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ABSTRACT
Apurinic/apyrimidinic endonuclease 1 (APE1) is the main mammalian AP-
endonuclease responsible for the repair of endogenous DNA damage through the 
base excision repair (BER) pathway. Molecular epidemiological studies have identified 
several genetic variants associated with human diseases, but a well-defined functional 
connection between mutations in APE1 and disease development is lacking. In order 
to understand the biological consequences of APE1 genetic mutations, we examined 
the molecular and cellular consequences of the selective expression of four non-
synonymous APE1 variants (L104R, R237C, D148E and D283G) in human cells. We 
found that D283G, L104R and R237C variants have reduced endonuclease activity and 
impaired ability to associate with XRCC1 and DNA polymerase β, which are enzymes 
acting downstream of APE1 in the BER pathway. Complementation experiments 
performed in cells, where endogenous APE1 had been silenced by shRNA, showed 
that the expression of these variants resulted in increased phosphorylation of histone 
H2Ax and augmented levels of poly(ADP-ribosyl)ated (PAR) proteins. Persistent 
activation of DNA damage response markers was accompanied by growth defects 
likely due to combined apoptotic and autophagic processes. These phenotypes were 
observed in the absence of exogenous stressors, suggesting that chronic replication 
stress elicited by the BER defect may lead to a chronic activation of the DNA damage 
response. Hence, our data reinforce the concept that non-synonymous APE1 variants 
present in the human population may act as cancer susceptibility alleles.
INTRODUCTION
Genomic integrity is constantly challenged by the 
action of exogenous and endogenous DNA damaging 
agents, such as ionizing radiation and reactive oxygen 
species generated by mitochondrial metabolism [1]. A link 
between loss of DNA repair function and carcinogenesis has 
been documented [2], and several epidemiological studies 
have implicated single nucleotide polymorphisms (SNPs) 
in DNA repair genes in cancer predisposition [3–5]. For 
instance, individual SNPs in Base Excision Repair (BER) 
proteins have been genetically correlated with colorectal, 
breast and lung cancer predisposition [5]. Moreover, 
it is likely that disease phenotypes may derive from a 
combination of variations in functionally coupled proteins, 
as in the case of DNA polymerase β (Polβ), X-ray repair 
cross-complementing protein 1 (XRCC1) and apurinic/
apyrimidinic endonuclease 1 (APE1), which would affect 
the capacity to repair DNA damage through the BER 
pathway [5–7]. Most polymorphisms in genes encoding 
BER proteins are low penetrance susceptibility alleles 
and a clear demonstration of the functional consequences 
in vivo of these polymorphisms is still missing.
APE1 is an essential enzyme that has a coordinating 
function in the BER pathway. It processes AP-sites 
generated by DNA glycosylases that remove damaged 
bases as the first step of BER. Loss of APE1 function 
will therefore lead to an accumulation of DNA repair 
intermediates that are both mutagenic and cytotoxic. 
Several non-synonymous APE1 genetic variants, e.g. 
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L104R, R237C, D148E and D283G, have been identified 
in the human population [5]. Among these APE1 missense 
variants, D148E is the most frequent SNP in the normal 
population [8]. L104R and D283G have been uniquely 
associated with amyotrophic lateral sclerosis (ALS), 
although the validity of these variants is a matter of debate 
[8, 9]. R237C is a variant associated with endometrial 
cancer [8, 10] (Table 1). With the exception of mutations 
at the catalytic residue D283, none of these substitutions 
occurs at residues responsible for known APE1 functions. 
It has been proposed that this may be related to a strong 
negative selection pressure elicited by the essential 
functions of APE1. However, no data are available to 
support this hypothesis at the molecular level. Interestingly, 
some polymorphisms occur in the N-terminal domain of 
APE1, a region harboring a number of residues that are 
subjected to post-translational modifications (PTMs) and 
are essential for a proper interaction with other proteins. 
This observation suggests that APE1 SNPs may indirectly 
impact on protein function by affecting its regulation 
or its ability to interact with specific binding partners 
[11–14]. To date, various studies have characterized the 
in vitro endonuclease and exonuclease activity of APE1 
mutants using recombinant proteins expressed in E. coli 
[8, 9, 15]. However, these studies were not designed to 
capture indirect consequences of amino acid substitutions 
that do not affect catalytic properties. Hence, a systematic 
characterization of the functional consequences of the 
expression of APE1 genetic variants is still missing. 
For a better understanding of the correlation 
between APE1 polymorphisms and susceptibility for 
disease, we characterized the impact of expressing L104R, 
R237C, D148E and D283G APE1 variants in HeLa cells 
where endogenous wild-type APE1 was silenced by 
shRNA. Here, we present data demonstrating that these 
variants severely impact on protein ability of binding to 
BER enzymes XRCC1 and Polβ. Expression of these 
APE1 genetic variants led to a persistent activation of the 
DNA damage response in the absence of exogenous DNA 
damaging agents, thus reinforcing the concept that APE1 
variants may act as cancer susceptibility alleles.
RESULTS
Computational evaluation of the effect of some 
polymorphic variants on APE1 structure and 
function
To guide functional characterisation, we evaluated 
the possible impact of a subgroup of APE1 polymorphisms 
(L104R, D148E, R237C and D283G) with respect to 
properties expected to affect protein structure and/or 
function; analysis was realized with four computational 
methods (PROVEAN [16], SIFT [17], PolyPhen-2 [18] and 
CUPSAT [19]). All the modeling algorithms (Figure 1A–1B 
and Table 1) predicted that 3 amino acid substitutions 
(i.e. L104R, R237C and D283G) would have an overall 
protein destabilizing effect or otherwise should affect APE1 
function (Table 1). The other polymorphism (i.e. D148E), 
although destabilizing, was considered to be tolerated and 
benign (Table 1). In agreement with these predictions, Hadi 
and colleagues and Illuzzi et al. previously demonstrated 
that D148E and L104R mutations do not show any altered 
AP-endonuclease activity in vitro [8, 9]. Interestingly, 
D148E and L104R have been shown to display strongly 
impaired 3′-RNA phosphatase and endoribonuclease 
activities, while their endonuclease activity towards DNA 
appeared unaffected [15, 20]. The R237C substitution was 
previously associated with a diminished APE1 activity 
in vitro [8] and it has been recently found to present reduced 
incision capacity in proximity of nucleosomes and at pre-
assembled DNA glycosylase/AP-DNA complexes [21]. 
Unaltered subcellular distribution of APE1 
genetic variants
None of the residues associated with these 
polymorphic variants is a candidate site for PTMs. Initial 
experiments were aimed at characterizing the above-
mentioned APE1 mutants in terms of protein expression 
level and subcellular distribution. To test a potential 
impact on intracellular localization, HeLa cells transiently 
transfected with plasmids expressing Flag-tagged 
APE1 variants were analyzed by immunofluorescence 
microscopy. All the variants displayed a subcellular 
distribution pattern comparable to that of the wild-type 
protein, with a predominant nucleoplasmic localization 
and an apparent nucleolar accumulation (Supplementary 
Figure S1), as previously shown by Illuzzi et al. [8]. 
To assess whether the expression of these APE1 
variants may impact on cell viability, we measured the 
fraction of living cells at 48, 72 and 96 h after transfection 
through the MTS assay. Expression of D148E and R237C 
variants resulted in a cell viability comparable to that of 
cells expressing wild-type APE1 (APE1WT), whereas cells 
expressing the L104R variant had a somewhat increased 
viability at 96 h (Figure 1C). On this basis, these variants 
do not seem to negatively impact on cell survival when co-
expressed with the endogenous APE1 protein. Hence, the 
variants do not appear to act as dominant negative alleles. 
With the exception of the D148E mutant, however, all 
variants had shorter half-lives compared to the ectopically 
expressed wild-type counterpart, when co-expressed with 
the endogenous APE1 (Supplementary Figure S2). This 
observation suggests that the presence of the endogenous 
protein may possibly mask an eventual negative impact of 
these variants.
APE1 genetic variants have reduced ability to 
form BER-competent complexes in HeLa cells
The different steps of the BER pathway are highly 
coordinated. XRCC1 protein serves as a scaffold to hand 
over the substrates between APE1 and the next enzyme 
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in the BER pathway, i.e. Polβ. Thus, we tested whether 
the ability of APE1 to engage a proper protein-protein 
interaction with XRCC1 and Polβ was impaired as result 
of protein polymorphisms. Four variants were selected for 
further analyses, based on the prediction that three of these 
mutants (L104R, R237C and D283G) were expected to 
impact on APE1 function, whereas D148E was predicted 
being tolerated and benign (Table 1).
































































































































For PROVEAN software (http://provean.jcvi.org/index.php), a cut-off score ≤ −2.5 is considered as deleterious, while a 
value greater than that is predicted as neutral. For SIFT modelling software (http://sift.jcvi.org/), a score ≤ 0.05 is considered 
as deleterious, whereas > 0.05 is predicted as tolerated. As template, the APE1 sequence (NP_001632.2) was used. For the 
PolyPhen-2 tool (http://genetics.bwh.harvard.edu/pph2/) and PROVEAN model, APE1 UniProtKB sequence (P27695) was 
used as query. CUPSAT predictions (http://cupsat.tu-bs.de/) were obtained by using the PDB APE1 crystallographic structure 
(1DE8) and the thermal experimental method. N/A = not available. Once = observed a single time. APE1 sequence entries 
reported above for computational analyses were identical and corresponded to the wild-type enzyme.
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Co-immunoprecipitation analyses were performed 
in HeLa cells transiently transfected with Flag-tagged 
APE1 expressing plasmids; the amounts of Polβ and 
XRCC1 immunoprecipitated together with each APE1 
variant was determined after normalization with respect 
to the corresponding FLAG-tagged variant levels before 
immunoprecipitation. The variant predicted to be tolerated, 
D148E, interacted with Polβ and XRCC1 as efficiently 
as APE1WT. The variants (L104R, R237C and D283G) 
predicted to impact on APE1 function showed a reduced 
ability to pull down Polβ and XRCC1 from the extracts 
(Figure 1D and Supplementary Figure S3), strongly 
suggesting a corresponding reduced capability to form 
BER complexes in cell culture. 
To test whether the AP-endonuclease activity of 
these immunopurified APE1 complexes was reduced, we 
used a DY782-labeled duplex DNA substrate that harbors 
a tetrahydrofuran residue mimicking a single abasic site at 
the central position [22]. In kinetics experiments (Figure 1E 
and Supplementary Figure S4A), the BER complex 
pulled down with APE1WT converted about 60% of the 
substrate within 10 min. In contrast, the complexes formed 
with R237C and L104R variants were able to cleave 
about 20% and 40% of the substrate, respectively. In 
agreement with a previous report [8], the D148E mutant 
presented no reduction in cleavage activity (Figure 1E 
and Supplementary Figure S4A). The D283G variant 
had no detectable cleavage activity under these assay 
conditions. However, measurements of product formation 
at increasing amounts of the D283G-immunoprecipitated 
BER-complex (Supplementary Figure S4B) confirmed 
that this variant is not a loss of function mutant; it simply 
showed a dramatically reduced activity, consistent with the 
requirement of the negatively-charged aspartate residue for 
efficient catalysis [9, 23].
Expression of APE1 genetic variants in HeLa 
cells impairs cell viability and growth 
Previous evaluation of the possible functional 
implications of APE1 variants, by using recombinant 
purified proteins in in vitro assays, showed no consistent 
correlation between APE1 activity and viability of cells 
transfected with the corresponding plasmids [8, 9]. One 
caveat of these experiments was that the possibility of a 
complementation effect provided by the presence of the 
endogenous APE1 protein could not be a priori excluded. 
The reduced half-life of these variants (Supplementary 
Figure S2) further suggested a possible masking effect 
of any deleterious phenotype associated with their 
expression.
To exclude this experimental bias, we established 
an experimental reconstitution strategy where the 
endogenous protein was silenced using small-hairpin (sh) 
RNA technology, concomitantly with the expression of 
shRNA-resistant APE1 variants (Figure 2A and 2B) [24]. 
Upon treatment with doxycycline for 9 days, we achieved 
an efficient silencing of the endogenous APE1 protein, 
with less than 10% residual expression (Figure 2B). 
All the subsequent analyses were performed in at least two 
independent clones for each APE1 variant. In agreement 
with the transient overexpression experiments and the 
measured reduced half-life, the expression levels of 
the different variants varied, with two mutants (R237C 
and D283G) showing lower expression levels than the 
ectopically expressed APE1WT (Supplementary Figure S2, 
top). Whereas the expression of APE1WT was well tolerated 
in this system, the growth of clones expressing the variants 
was impaired, as evident from measuring the corresponding 
growth rate by cell counting (Figure 2C) or colony-forming 
ability (Supplementary Figure S5A). No correlation was 
observed between growth impairment and expression 
level of the different variants; in fact, no significant 
differences in the growth rate of clones expressing L104R, 
R237C and D283G variants were measured. Since low 
levels of APE1 expression were previously demonstrated 
to sustain cell growth [25], the reduced growing we 
observed seemed likely associated with the expressed 
variant per se. Moreover, the measured slow growth rates 
were associated with a slight increased G2- and S-phase 
permanence, especially for L104R- and D283G-expressing 
cells (Figure 2D, top). Within the cycling population, a 
decrease in the ratio between cells in the G1 and S+G2 
phases was detected (G1/S+G2 ratio: WT, 0.88; L104R, 
0.64; R237C, 0.87; D283G, 0.63), suggesting a possible 
minor impairment in the passage to the following G1-
phase, due to the expression of these APE1 variants. In 
accordance, Western blot analyses showed p21 and Gadd45 
stabilization under basal conditions in the clones expressing 
APE1 genetic variants, thus suggesting an induced check 
point activation under basal conditions (Figure 2D, bottom). 
The altered proliferation indexes observed for all the 
genetic variants were accompanied by increased fractions 
of necrotic (Figure 2E) and apoptotic (Figure 2F) cells 
under basal conditions, as measured by FACS analysis 
(Supplementary Figure S5B).
Expression of APE1 genetic variants leads to 
impaired rRNA biogenesis and induction of 
autophagy 
As the minor perturbations observed in the cell-
cycle progression were unlikely in explaining the 
observed reduction in growth, we tested whether the 
expression of these variants was impacting on other cell 
parameters related to APE1 functions. To test whether 
expression of APE1 mutants in APE1 expressing cell 
clones interfered with ribosome biogenesis [12, 26–28], 
we assessed the corresponding nucleolar incorporation 
of the fluorinated UTP analogue fluorouridine 
(FUrd) into nascent rRNA transcripts [26, 29, 30]. 
Expression of these genetic APE1 variants resulted 
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Figure 1: Substitution mutations in APE1 affects protein function. (A and B) APE1 amino acid substitutions and corresponding 
localization within the APE1 structure. Position of the APE1 mutations in a linear sequence (A) and three-dimensional protein representation 
(B). The first 33 residues involved in protein-protein interaction, the redox regulatory region and the nuclease domain are shown (A). The 
coordinates of the protein structure were retrieved from the protein data bank (PDB) accession 4IEM. The amino acids discussed in this 
study are labeled and shown in a stick representation (B). (C) Cell viability at increasing times after transfection of HeLa cells overexpressing 
each APE1 variant was determined by colorimetric (MTS) assay. Data represent the mean ± SD of three independent experiments. 
(D) Expression of L104R, R237C and D283G negatively affects APE1 protein-protein interaction. Representative Western blot analysis on co-
immunoprecipitated proteins from HeLa cells overexpressing APE1 genetic variants. Co-immunoprecipitated proteins were detected by Western blotting 
using specific antibodies, as indicated on the right-hand side. FLAG was used as loading control (top). Histograms report the normalized values for the 
association of the different APE1 variants (horizontal axis) with the protein interacting partners. APE1WT was used as a reference (by attributing a 100% 
interaction value). Mean ± SD values are the results of three independent experimental sets (bottom). Student’s t-test calculation was performed on three 
independent experiments to assess the significance between APE1WT and genetic variants, as indicated; *p ≤ 0.05; ns, non-significant. IP, immunoprecipitate. 
(E) AP endonuclease incision activity of APE1 genetic variants. Relative AP-incision efficiency in time-dependent kinetics for APE1WT and variant APE1 
immunoprecipitates. Mean ± SD values are the results of three independent experimental sets (top). Student’s t-test calculation was performed on three 
independent experiments to assess the significance between APE1WT and genetic variants, as indicated; *p ≤ 0.05; ns, non-significant. A Western blot 
analysis on APE1 immunoprecipitates was used for normalization of the results from AP endonuclease incision assays (bottom). 
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Figure 2: Expression of APE1 variants results in a reduced cell viability and growth defects. (A) Knock-in strategy for 
the generation of APE1 genetic variants stable cell clones. HeLa cells were used as a general cellular model and subjected to reiterative 
transfection cycles for the stable acquisition in series of: a) a Tet repressor constitutively expressed; b) a specific APE1 shRNA under the 
control of a doxycycline-responsive promoter; c) shRNA-resistant FLAG-tagged APE1 genetic variants under the control of a doxycycline-
responsive promoter. Adding doxycycline to the culture medium allowed the expression of the APE1 shRNA, with the subsequent silencing 
of the endogenous protein and the concomitant expression of the ectopic counterpart. (B) Suppression of endogenous APE1 and expression 
of APE1 genetic variants in HeLa stable cell clones. Representative Western blot analysis of APE1 genetic variants from stable cell clones 
silenced for endogenous APE1. Two clones for each polymorphism were assayed (data not shown). Levels of endogenous (endo) or ectopic 
(ecto) proteins were detected with specific antibodies, as indicated on the right-hand side. Tubulin was used as loading control. (C) Clones 
expressing APE1 genetic variants have a growth defect. Growth was followed through Trypan blue staining by measuring cell numbers 
at the indicated times upon doxycycline treatment. Data, expressed as cell number, are the mean ± SD of three independent experiments. 
Student’s t-test calculation on three independent experiments was performed to assess the significance between APE1WT and genetic variants, 
as indicated; *p ≤ 0.05. (D) Cell cycle distribution. Analysis of the distribution into various stages of the cell cycle in clones expressing 
APE1 genetic variants after 9 days of doxycycline treatment. G1, S and G2 phases are indicated. Mean ± SD values are the results of three 
independent experiments. Below, Western blots showing increased expression of cell cycle arresting regulators p21 and Gadd45 in whole cell 
extracts of APE1 cell clones. Tubulin was used as loading control. (E and F) Cell necrosis and apoptosis. To measure the fraction of apoptotic 
and necrotic cells, clones expressing APE1 genetic variants were grown for 9 days with doxycycline, labeled with Annexin V FITC and PI 
to monitor apoptosis and necrosis, respectively, using FACS analysis. The fraction (%) of necrotic (E) and apoptotic (F) cells is plotted in 
histograms. Bar graph shows the average of 3 independent experiments ± SD. Asterisks represent a significant difference (p ≤ 0.05) with 
respect to APE1WT. As positive control for apoptosis, we used clones expressing APE1WT treated with 200 μM etoposide for 24 h (etop). 
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in a reduced nucleolar FUrd uptake (Figure 3A), 
which is a phenotype associated with nucleolar stress. 
Moreover, expression of the R237C and D283G variants 
led to the formation of nucleolar ring structures (Figure 3A, 
right), which are typical indications of autophagic activity 
in the nucleolar caps [31–33]. Thus, we monitored the 
induction of autophagy in clones reconstituted with APE1 
variants by following LC3-I to LC-II conversion after 
treatment with 3-methyladenine (Figure 3B) and LC3 
puncta formation (Supplementary Figure S6A). Silencing 
of APE1 itself resulted in a reduction of p62 levels, but it 
was not associated with a significant increase of the LC3 
cleavage (Supplementary Figure S6B). Reconstitution of 
these cells by the expression the APE1 variants resulted 
in a weak, though consistent, increase in LC3-II cleavage 
(Figure 3B), in agreement with an induction of autophagy. 
To exclude any bias due to the possible onset of adaptive 
phenomena in the reconstituted clones, we monitored 
p62 levels and lysosomal turnover of LC3 in transiently 
transfected HeLa cells treated with the lysosomal protease 
inhibitors E64D and pepstatin A [34]. Expression of the 
APE1 variants resulted in a 1.5 to 2.5-fold increase in LC3-
II formation, compared to cells expressing APE1WT, while 
no marked accumulation of p62 was observed (Figure 3C). 
These data confirmed the observed increased autophagic 
flux in cells expressing these APE1 variants. To assess the 
activation of other pathways that may negatively impact on 
cell growth [35, 36], we monitored the senescence Ki-67 
marker upon expression of these APE1 variants [37]; no 
significant changes were observed in this case (Figure 3D). 
On the other hand, a mild induction of the apoptotic 
program, as measured by PARP1 cleavage (PARP1cv) 
(Figure 3E) and by previous FACS analysis (Figure 2F), 
was observed in all clones and in cells transiently 
transfected with these APE1 variants (Supplementary 
Figure S6C). On this basis, a combined occurrence of 
slow cell-cycle progression, induction of autophagy and 
apoptotic/necrotic events was claimed to account for the 
slow-growing phenotype of cells expressing the above-
mentioned APE1 genetic variants.
APE1 genetic variants showed altered resistance 
to genotoxic damages
As these APE1 genetic variants had reduced 
capacity to form BER-competent complexes and showed 
reduced AP-endonuclease activity (Figure 1D and 1E 
and Supplementary Figure S4A), we tested whether the 
cells expressing these mutants were sensitive to MMS, an 
agent generating lesions that are repaired by BER [38–41]. 
Contrary to all expectations, MTS assays demonstrated 
that all the clones expressing APE1 variants were less 
sensitive to MMS, compared to cells expressing APE1WT 
(Figure 4A). The protective effect towards MMS was 
confirmed using the colony formation assay (Figure 4B) 
and FACS analysis (Figure 4C), showing an increased 
fraction of apoptotic cells in APE1WT-expressing clones. 
A similar effect was also observed in cells treated with 
cisplatin, a DNA crosslinking agent generating ROS and 
oxidative DNA lesions that are repaired through BER, with 
the essential involvement of APE1 [39, 41–44] (Figure 4D 
and Supplementary Figure S7A–S7B). Thus, expression 
of APE1 variants did not result in hypersensitivity to 
genotoxins. Instead, a mild tolerance to DNA damaging 
agents was observed that is likely associated with the slow 
growing phenotype or with the nucleolar stress induced by 
these agents. 
Increased poly(ADP-ribosyl)ation and DNA 
damage levels in APE1 genetic variants
In the above, we have shown that the expression 
of APE1 variants leads to growth defects which are 
accompanied by slow cell-cycle progression, nucleolar 
stress, induction of autophagy and an increased basal 
activation of apoptosis. These phenotypes may be linked 
to and be suggestive for a condition of a cellular stress as a 
consequence of inefficient processing of endogenous DNA 
damage. To test this hypothesis, we measured the levels of 
two well-established markers of DNA damage response 
activation, γH2Ax and poly(ADP-ribosyl)ated (PAR) 
proteins, in clones re-expressing these APE1 variants. In 
this context, PAR proteins are considered as biomarkers of 
PARP1 activation [45]. All the genetic variants displayed 
a robust increase in both markers, when compared to 
clones expressing APE1WT (Figure 5). In particular, PAR 
levels were increased about 8-fold and much higher than 
counterparts measured in cells treated with etoposide 
(Etop); similarly, γH2Ax levels were increased about 4-fold 
(Figure 5). Analogous results were observed upon transient 
expression of these variants in HeLa cells (Supplementary 
Figure S8). Thus, the expression of these APE1 mutants 
seemed to elicit a chronic induction of DDR signaling, 
which may explain the slow cell-cycle progression and 
growth defects we observed. Importantly, these phenotypes 
were observed in cells in the absence of genotoxin exposure, 
emphasizing the importance of efficient BER to protect 
cells against endogenous DNA damage. The phenotypes 
activated in response to this stress likely contribute to a 
tolerance to additional stressors (Figure 4). The chronic 
genomic stress induced by the expression of APE1 variants, 
resulting in persistent activation of the DDR, would also be 
expected to set up a selective pressure towards loss of DNA 
damage checkpoint mechanisms, thus suggesting a rationale 
for the seemingly paradoxical slow-growing phenotype 
observed in cell culture and an eventual association with 
human cancer. 
DISCUSSION
Recent studies have identified correlations between 
defects in APE1 and predisposition to human diseases, 
including cancer [5]. Although severe deficiencies in 
APE1 are incompatible with life in mammals, several 
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Figure 3: Impaired rRNA biogenesis and induction of autophagy in HeLa cells expressing APE1 genetic variants. 
(A) Expression of R237C and D283G variants leads to nucleolar stress. FUrd labeling of reconstituted cell lines 9 days after doxycycline 
treatment. Representative immunofluorescence images showing impaired FUrd accumulation and preferential nucleolarcap formation 
(left). Histogram reporting percentage of cells with FUrd nucleolar incorporation and nucleolar caps in the different clones (right). Bar 
graph shows the average of 3 independent experiments ± SD. *p ≤ 0.05; ns, non-significant. (B) Induction of autophagy. Western blots 
showing autophagy induction in APE1 cell clones by monitoring LC3-I to LC3-II conversion in the absence (−) or presence (+) of 
3-methyladenine (5 mM for 9 h) in whole cell extracts. Tubulin was used as loading control (top). LC3-I and LC3-II bands were normalized 
to those of tubulin; relative LC3-II/LC3-I levels in the different clones were determined after normalization to corresponding value of 
APE1WT (bottom). Bar graph shows the average of 3 independent experiments ± SD. *p ≤ 0.05; ns, non-significant. (C) R237C and D283G 
variants induce autophagy in transient transfected HeLa cells. Western blots showing autophagy induction in transiently transfected HeLa 
cells expressing APE1 genetic variants through the monitoring of LC3-II and p62 levels in whole cell extracts. Cells were treated with 
E64D (10 μg/ml) and pepstatin A (10 μg/ml) for 2 h before harvesting. Levels of endogenous (endo) or ectopic (ecto) proteins were 
detected with specific antibodies, as indicated on the right-hand side. Actin was used as loading control (left). LC3-II and p62 bands were 
normalized to those of tubulin; relative quantification of LC3-II and p62 levels in the different clones was determined after normalization 
to corresponding values of APE1WT (right). Student’s t-test calculation on three independent experiments was performed to assess the 
significance between APE1WT and genetic variants, as indicated; *p ≤ 0.05; **p ≤ 0.005; ns, non-significant. (D) Cellular senescence does 
not contribute to growth defect. Assessment of Ki-67 as marker of senescence in APE1 variants-reconstituted cell lines after 8 days of 
doxycycline treatment. Representative immunofluorescence images of Ki-67 (left). Mean of quantitative estimates of Ki-67 negative cell 
fraction within the clones (right). Bar graph shows the average of 3 independent experiments ± SD. (E) Expression of APE1 variants leads 
to an increased basal PARP1 cleavage. Representative Western blots showing cleaved PARP1 (PARP1cv) in cell lines reconstituted with 
APE1 genetic variants. Tubulin was used as loading control (left). PARP1cv levels were quantified and normalized to the corresponding 
values of APE1WT (right). As positive control for PARP1 cleavage, we used clones expressing APE1WT treated with 200 μM etoposide for 
24 h (etop). 
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Figure 4: Clones expressing APE1 genetic variants are less sensitive towards genotoxic damage. (A) Cell viability of 
APE1 variants-reconstituted clones subjected to treatment with increasing amounts of MMS was determined by a colorimetric (MTS) 
assay. Data presented using a logarithmic scale showing the mean ± SD of three independent experiments. (B) Cell growth of APE1 
variants-reconstituted clones subjected to treatment with increasing amounts of MMS was measured by the colony formation assay. Data, 
expressed as the percentage of change with respect to untreated clones, are the mean ± SD of three independent experiments. (C and D) 
Clones expressing APE1 genetic variants were grown for 9 days with doxycycline and treated with increasing doses of MMS for 8 h (C) 
and cisplatin for 24 h (D), as indicated. Apoptosis was assayed with PI staining and is reported as fold change of induction with respect to 
each untreated clone. Bar graph shows the average fold of induction of apoptosis in 3 independent experiments ± SD, as normalized with 
respect to untreated clones. Asterisks represent a significant difference respect to APE1WT.
Figure 5: Expression of APE1 variants leads to a basal activation of the DNA damage response. Representative Western 
blots showing PAR protein and γH2Ax levels in APE1 genetic variant-reconstituted cell lines upon doxycycline treatment. Tubulin was 
used as loading control (left). Quantification of PAR protein and γH2Ax levels was obtained after normalization to APE1WT (right). As 
positive control, we measured PAR protein and γH2Ax levels in clones expressing APE1WT treated with 200 μM etoposide for 24 h (etop). 
All the clones displayed a statistically significant change (p ≤ 0.05) in PAR protein and γH2Ax levels, considering APE1WT as reference. 
Bar graph shows the average of 3 independent experiments ± SD. 
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APE1 SNPs have been identified [5], but epidemiological 
studies have reported conflicting associations with disease. 
In vitro data are available for functional and structural 
consequences of several APE1 variants [8, 15]. In this 
study, we provide evidence for a biological effect in 
cultured cells of some of these mutations. 
We characterized the molecular and cellular 
phenotypes arising as a result of the expression of a group 
of APE1 genetic variants (summarized in Table 2). Except 
for the D283G mutant, these variants involve amino acids 
that do not appear directly responsible for either APE1 
AP-endonuclease activity or its redox-regulatory function. 
These mutants presented a nuclear subcellular localization 
indistinguishable from that of APE1WT, demonstrating 
that none of these amino acid substitutions affects the 
distribution of the protein itself. However, we observed a 
marked reduced cell growth in clones expressing these APE1 
variants, where the expression of the endogenous protein 
was suppressed using shRNA. These conditions recapitulate 
a heterozygous situation, where APE1 variants are observed 
in human population. In experimental models we set up 
for mimicking a heterozygous or homozygous situation, 
the expression of these variants caused the formation of 
nucleolar caps structures and other markers associated 
with autophagic activation. On this basis, it is possible to 
hypothesize that, concomitantly with mutant expression, 
proteins associated with damaged DNA are removed from 
the nucleolus via autophagy, as recently suggested for other 
DNA repair proteins [46, 47]. However, further studies 
would have to confirm whether this is the case for these 
APE1 variants or whether the induction of autophagy is a 
consequence of an increased endogenous stress.
Evidence of elevated levels of endogenous genotoxic 
stress was observed in both heterozygous and homozygous 
model. Augmented γH2AX levels and increased PARP1 
activation were consistent with the induction of replicative 
stresses due to an inefficient repair of endogenous DNA 
damage through the BER pathway. Such an effect would 
explain the slow-growing phenotype we observed [48, 
49] and the seemingly contradictory finding of tolerance 
to treatment with genotoxic agents. 
An impaired APE1 endonuclease activity and a 
consequent reduced BER capacity were observed also 
in variants not associated with cancer [43]. APE1 also 
contributes to the regulation of cellular responses to 
oxidative stress and has other non-DNA repair activities, 
such as the regulation of the expression of genes involved 
in chemo-resistance and tumor progression through 
transcriptional and post-transcriptional mechanisms [50]. 
Through its redox activity towards different cancer-related 
transcription factors, APE1 is also involved in the regulation 
of inflammatory and metastatic processes [50]. Thus, factors 
not directly related to BER function are likely to shape the 
phenotypes associated with APE1 variants. Control of 
APE1 functions is multi-layered and involves PTMs and 
complex formation with APE1-associated proteins. Hence, 
a reasonable explanation for the reduced AP-endonuclease 
activity and for the phenotypes observed after the expression 
of these APE1 variants may be ascribed to an alteration of 
the corresponding protein interactomes. An impact for these 
polymorphisms on APE1 ribosomal function(s) cannot be 
excluded. By shaping the corresponding protein interactome 
beyond the BER-interactome studied here, APE1 amino 
acid substitutions can significantly affect the corresponding 
biological effects. An active role for APE1 and, possibly, 
for other BER enzymes, in the regulation of ribosome 
biogenesis [26, 51] would likely also affect cell sensitivity 
to DNA damaging agents. 
However, the phenotypes described here are all 
consistent with an interpretation that above-mentioned 
APE1 variants have a reduced ability to engage BER 
competent complexes. PARP1 activation and increased 
basal phosphorylation of H2AX indicated that this 
impaired BER function was eliciting a situation of chronic 
endogenous genotoxic stress. We here propose that the 
persistent activation of PARP1 and the accumulation of 

































L104R + + + ↓ + + + + +
D148E − − − − − N.D. N.D. + +
R237C ++ + + ↓ ++ − + ++ ++
D283G +++ + + ↓ +++ + + +++ +++
N.D., not determined.
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DNA damage beyond a certain threshold of physiological 
DNA repair limit, as well as the induction of autophagy, 
might create a positive niche for tolerance phenomena 
and the establishment of cancer cells. This background 
activation of the DDR may also create an evolutionary 
pressure that might affect cancer susceptibility in cells 
expressing APE1 variants.
MATERIALS AND METHODS
Inducible APE1 knock-down and generation of 
APE1 knock-in cell lines
Inducible silencing of endogenous APE1 and 
reconstitution with APE1 genetic variants in HeLa cell 
clones was performed as already described [14] and 
detailed in Supplementary Information. Cell clones were 
grown for 9 days as indicated [14]. All biological data 
were reproduced at least in two different cell clones for 
each APE1 variant.
Cell culture, treatments and plasmid transfection 
HeLa cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) (Invitrogen, Carlsbad, CA) 
supplemented with 10% foetal bovine serum (Euroclone, 
Milan, Italy), 100 U/ml penicillin, and 10 μg/ml 
streptomycin sulfate. Cisplatin was freshly solved in 
dimethylformamide before use. Pepstatin A and E64D were 
purchased from Vinci-Biochem (Florence, Italy) and solved 
in dimethyl sulfoxide. 3-Methyladenine and bafilomycin A 
were purchased from Sigma-Aldrich (Oslo, Norway) and 
solved in water and dimethyl sulfoxide, respectively. Cell 
transfection was performed as described previously [52]. 
All chemical reagents were supplied from Sigma-Aldrich 
(Milan, Italy) unless otherwise specified.
Preparation of the cell extracts and Western 
blotting
Whole cell extracts for Western blotting analyses were 
prepared as previously described [12]. Membranes were 
developed by using the ECL enhanced chemiluminescence 
procedure (GE Healthcare, Piscataway, NJ) or by using 
the NIR Fluorescence technology (LI-COR GmbH, 
Germany), as indicated in each figure capture. Images 
were acquired and quantified by using a Chemidoc XRS 
video densitometer (Bio-Rad, Hercules, CA) or an Odyssey 
CLx Infrared Imaging system (LI-COR GmbH, Germany). 
A list of antibodies used is given in the Supplementary 
Information.
Co-immunoprecipitation
Co-immunoprecipitation analyses were performed 
as already described [14, 26]. 
APE1 plasmid constructs
Expression constructs for human APE1 variants were 
created using the QuikChange II Site-Directed Mutagenesis 
Kit (Stratagene, Santa Clara, CA). Forward and reverse 
primers containing the relevant nucleotide change were 
generated following the mutagenic primer design guidelines 
of the manufacturer. All the mutants were confirmed by 
DNA sequencing (MWG, Ebersberg, Germany).
Cell viability, cell growth and clonogeneic assays
Cell viability was measured through the MTS assay 
(CellTiter 96 AQueous One Solution Cell Proliferation 
Assay; Promega, Madison, WI) according to manufacturer’s 
instructions. Cell growth and clonogenic assays were 
performed as described previously [12, 53].
Assessment of nucleolar transcription
Fluorouridine (FUrd) incorporation was assessed as 
described previously [26, 29, 30]. 
Cell-cycle and apoptotic analysis
Following doxycycline treatment, HeLa cells 
reconstituted with the APE1 variants were harvested, washed 
once with ice-cold PBS and fixed at 1 × 106 cells/ml in cold 
70% ethanol, at 4°C, overnight. Cells were centrifuged at 
200 × g for 10 min, at 4°C, and washed twice with ice-cold 
PBS. Cell pellets were resuspended in a sodium azide/PBS 
solution containing propidium iodide (PI) (0.04 mg/mL) 
(Invitrogen, Carlsbad, CA, USA), DNase free RNase A 
(0.2 mg/mL) (Sigma-Aldrich, Milan, Italy) and 0.1% w/v 
Triton X-100, and then incubated for 15 min, at 37°C, in 
the dark, with gentle mixing every 5 min. For apoptotic 
analysis in response to MMS and cisplatin treatment, cells 
were trypsinized, washed once with ice-cold PBS and 
immediately resuspended in PBS/sodium azide solution 
containing PI (0.04 mg/mL propidium iodide) (Invitrogen, 
Carlsbad, CA, USA). For the evaluation of necrosis 
and apotosis, cells were doubly stained using Annexin 
V-FITC and PI (Apoptosis Detection Kit; eBioscience, # 
BMS500FI) according to manufacturer´s instructions. Cell 
cycle analyses and quantification of apoptotic cells were 
performed by flow cytometric analysis using a FACScan 
(Becton Dickinson, Franklin Lakes, NJ, USA). For each 
sample, 25,000 single events /cells were detected and data 
analysis was performed using FCS Express 4 Plus research 
edition software (De Novo Software, Los Angeles, CA).
AP-incision assay
AP-nicking assays were performed essentially as 
previously described [14]. To measure AP- endonuclease 
activity, 0.75 pmol of 5′DY782 26F DNA oligonucleotide 
were reacted with 0.75 fmol of APE1WT or variant APE1 
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immunoprecipitates in 50 mM HEPES, 50 mM KCl, 
10 mM MgCl2, 1 μg/ml bovine serum albumin and 0.05% 
w/v Triton X-100 at 37°C, for the indicated times. For the 
dose-response experiments, the indicated amounts of D283G 
immunoprecipitates were incubated for 10 min, at 37°C. Gels 
were visualized with an Odyssey CLx Infrared Imaging system 
(LI-COR GmbH, Germany). The signals of the non-incised 
substrate (S) and the incision product (P) bands were quantified 
using Image Studio software (LI-COR GmbH, Germany).
Statistical analyses
Statistical analyses were performed by using the 
Student’s t test. P < 0.05 was considered as statistically 
significant.
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